Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma Journal Article

   

Authors:	Thomas, A. A.; Abrey, L. E.; Terziev, R.; Raizer, J.; Martinez, N. L.; Forsyth, P.; Paleologos, N.; Matasar, M.; Sauter, C. S.; Moskowitz, C.; Nimer, S. D.; Deangelis, L. M.; Kaley, T.; Grimm, S.; Louis, D. N.; Cairncross, J. G.; Panageas, K. S.; Briggs, S.; Faivre, G.; Mohile, N. A.; Mehta, J.; Jonsson, P.; Chakravarty, D.; Gao, J.; Schultz, N.; Brennan, C. W.; Huse, J. T.; Omuro, A.
Article Title:	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma
Abstract:	Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day © 2017 The Author(s).
Keywords:	temozolomide; autologous stem cell transplant; anaplastic oligodendroglioma; 1p/19q codeletion
Journal Title:	Neuro-Oncology
Volume:	19
Issue:	10
ISSN:	1522-8517
Publisher:	Oxford University Press
Date Published:	2017-10-01
Start Page:	1380
End Page:	1390
Language:	English
DOI:	10.1093/neuonc/nox086
PROVIDER:	scopus
PMCID:	PMC5596171
PUBMED:	28472509
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030786842&doi=10.1093%2fneuonc%2fnox086&partnerID=40&md5=7e21d2f25dec53cb973dc2157f37fb5b
Notes:	Article -- Export Date: 2 November 2017 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/116629